; (2) collaborate with the Director of the Centers for Disease Control and Prevention, as applicable and appropriate, and other Federal agencies with relevant expertise as appropriate; and (3) provide for a notice and comment period consistent with section 701(h) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 371(h) ) for the submission of comments by the public. (c) Report Not later than 1 year after the date of enactment of this Act, or, if earlier, at the time the guidelines under subsection (a) are finalized, the Commissioner of Food and Drugs shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate, and post on the public website of the Food and Drug Administration, a report on how the Food and Drug Administration will utilize the guidelines under subsection (a) to protect the public health and a description of the public health need with respect to each such indication-specific treatment guideline. (d) Updates The Commissioner of Food and Drugs shall periodically— (1) update the guidelines under subsection (a), informed by public input described in subsection (b); and (2) submit to the committees specified in subsection (c) and post on the public website of the Food and Drug Administration an updated report under such subsection. (e) Statement To accompany guidelines and recommendations The Commissioner of Food and Drugs shall ensure that opioid analgesic prescribing guidelines and other recommendations developed under this section are accompanied by a clear statement that such guidelines or recommendations, as applicable— (1) are intended to help inform clinical decisionmaking by prescribers and patients